Florida Regulations 2-40.007: Rescheduling of a Drug Product in Finished Dosage Formulation That Has Been Approved by the U.S. Food and Drug Administration That Contains Cannabidiol (2-[1R-3-methyl-6R-(1-methylethenyl)-2-cyclohexen-1-yl]-5-pentyl-1,3…
Current as of: 2024 | Check for updates
|
Other versions
Under the authority of section 893.0355, Florida Statutes, a drug product in finished dosage formulation that has been approved by the U. S. Food and Drug Administration that contains cannabidiol (2-[1R-3-methyl-6R-(1-methylethenyl)-2-cyclohexen-1-yl]-5-pentyl-1,3-benzenediol) derived from cannabis and no more than 0.1 percent (w/w) residual Tetrahydrocannabinols, is hereby rescheduled from a Schedule I to a Schedule V controlled substance.
Rulemaking Authority 893.0355 FS. Law Implemented Florida Statutes § 893.0355. History-New 2-7-19.
Rulemaking Authority 893.0355 FS. Law Implemented Florida Statutes § 893.0355. History-New 2-7-19.